In The News
- Steve Pakola on Leading Clinical Development Programs for Rare Diseases and Gene Therapies
- REGENXBIO Announces First Patient Dosed in Phase IIb/III NAAVIGATE Trial of Surabgene Lomparvovec in Diabetic Retinopathy; Company to Receive $100 Million Milestone
- Steve Pakola: The Physician Who Chose Discovery Over the Exam Room — and Never Looked Back
- Steve Pakola and the Long Game of Gene Therapy
- REGENXBIO Announces Positive Topline Results from Pivotal Phase III AFFINITY DUCHENNE® Study of RGX-202
- REGENXBIO Announces Completion of Enrollment in Pivotal Trials of Subretinal Surabgene Lomparvovec for Wet AMD
- REGENXBIO Announces Pivotal Program for Surabgene Lomparvovec in Diabetic Retinopathy